Should you buy Moderna stock as it develops a vaccine for the Omicron variant?

Invezz

Published

On Monday, Moderna Inc. (NASDAQ:MRNA) shares edged higher after revealing plans to develop a vaccine for the Omicron variant.  The stock surged nearly 10% after it said a new covid vaccine targeting the Omicron variant could be ready by early 2022. Moderna had rocketed more than 21% on Friday amid fears of the potential impact […]

Full Article